Trial Profile
Phase2/3 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer(PEGASUS-PC Study).
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Dec 2014
Price :
$35
*
At a glance
- Drugs Elpamotide (Primary) ; Gemcitabine
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Expanded access; Therapeutic Use
- Acronyms PEGASUS-PC
- Sponsors OncoTherapy Science
- 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
- 26 Jan 2013 Primary endpoint 'Overall-survival-duration' has not been met.
- 12 Jun 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan. (Parent trial: UMIN000001664)